NUDT1 and cancer: Taken collectively, the reported discrepancies among recent studies characterizing MTH1 inhibitors in cancer models reinforce the idea (supported in part by our findings) [26,27] that MTH1 inhibition-associated outcomes rely on several key molecular factors.